Weekly Digest - September 2024
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
Weekly Digest - September 2024
3 Sep 2024: Avenzo Therapeutics partners with Gilead Sciences for clinical study to evaluate AVZO-021 and Trodelvy in HR+/HER2- Metastatic Breast Cancer
- Avenzo Therapeutics and Gilead Sciences have entered a collaboration to evaluate AVZO-021, a CDK2 inhibitor, in combination with Gilead’s Trop-2 directed ADC, Trodelvy
- The combination will be assessed in a Phase 1/2 study for HR+/HER2- metastatic breast cancer
- Avenzo will sponsor the trial and Gilead will provide Trodelvy and the combination cohorts are set to begin in Q4 2024
- Both companies will retain development and commercial rights for their respective compounds
